News

Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details

Phase III carfilzomib trial meets primary endpoint

Amgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…

Details

SMC approves restricted use of daratumumab monotherapy for relapsed and refractory myeloma

The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex®) monotherapy as a fourth line treatment option for relapsed and refractory myeloma patients in Scotland, who have previously received treatment with a proteasome inhibitor and immunomodulatory drug. This decision is based on the pooled analysis of results from two clinical trials, MMY2002 and…

Details

Genmab report positive results from Phase III daratumumab trial for myeloma patients

The Danish biotechnology company, Genmab, have announced that the Phase III trial, ALCYONE, has achieved its primary endpoint of improving progression-free survival in newly diagnosed myeloma patients. This study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone. Treatment including daratumumab was demonstrated to reduce the risk of disease…

Details

Carfilzomib combination approved for use in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared…

Details

Lenalidomide maintenance treatment demonstrates significant overall survival benefit following HDT-ASCT

Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…

Details

SKY92 validated as a useful prognostic tool for myeloma patients

A study, published recently in Clinical Lymphoma, Myeloma and Leukemia, has further validated the use of the SKY92 gene expression signature as a potentially valuable prognostic tool to evaluate myeloma patients. Compared with seven other gene expression profiling classifiers including UAMS 70, UAMS 80 and IFM15, the researchers found that SKY92 identified the largest proportion (21%)…

Details